Study of SGR-1505 in Mature B-Cell Neoplasms

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

Trial Details

NCT ID
NCT05544019
Phase
PHASE1
Sponsor
Schrödinger, Inc.
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • SGR-1505
Locations (sample)
  • Gilbert, Arizona, United States|33.35283,-111.78903
  • Newark, Delaware, United States|39.68372,-75.74966
  • Pompano Beach, Florida, United States|26.23786,-80.12477
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Hackensack, New Jersey, United States|40.88593,-74.04347

Key Eligibility Criteria

  • Subject must have a history of histologically or cytologically confirmed mature B-cell malignancy.
  • Subject must have measurable or detectable disease according to the applicable disease-specific classification system and meet criteria for initiat…
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Life expectancy ≥ 12 weeks.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →